Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01106677 · ClinicalTrials.gov registry record · Phase 3
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,284
- Enrollment target
NCT01106677 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 1,284 participants.
The verdict
NCT01106677, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,284 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin and placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (i.e., treatment with a single drug) and have inadequate glycemic (blood sugar) control.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG Canagliflozin
- DRUG Metformin immediate release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,284 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01106677
The ClinicalTrials.gov registry entry for NCT01106677 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,284 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01106677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01106677 about?
NCT01106677 is a clinical study titled "The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)". The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin and placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (i.e., treatment with a single drug) and have inadequate glycemic (blood sugar) con...
What is the current status of trial NCT01106677?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,284 participants. The study started on 2010-05. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01106677?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), Canagliflozin (DRUG), Metformin immediate release (DRUG).
Who is sponsoring clinical trial NCT01106677?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.